drugset
drugset / Trial / NCT07007780

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

NCT07007780 ↗

Phase 2 Not yet recruiting 35 enrolled Xijing Hospital
NaSingle-groupOpen-labelTreatment

Summary

To explore the application of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Sacituzumab Tirumotecan and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.

Timeline

Start
2025-08-20
Primary completion
2026-08-31
Completion
2027-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacituzumab Tirumotecan Other / unclassified 5 mg/kg —

Indications

triple-negative breast carcinoma